Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors

Journal of Neuroscience

Volumn 22, Issue 3, 2002, Pages 1146-1154

  Ghozland, Sandy ^a   Matthes, Hans W D ^a   Simonin, Frederic ^b   Filliol, Dominique ^b   Kieffer, Brigitte L ^a,b   Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b CNRS   (France)

Author keywords

Dependence; Knock out; Place aversion; Place preference; Reward; Tolerance; 9 tetrahydrocannabinol

Indexed keywords

CANNABINOID; DELTA OPIATE RECEPTOR; DRONABINOL; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; AVERSION; CONDITIONING; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPHORIA; EUPHORIA; FEMALE; HYPOTHERMIA; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOTIVATION; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD;

EID: 0036470141     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-03-01146.2002     Document Type: Article

References (53)

1. κ receptors mediate the peripheral aversive effects of opiates
2. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1
3. The functional neuroanatomy of brain cannabinoid receptors
4. Δ9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis
5. CB1 receptor antagonist precipitates withdrawal in mice exposed to Δ9-tetrahydrocannabinol
6. Δ-9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat
7. Δ9-tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus
8. The role of dopamine in drug abuse viewed from the perspective of its role in motivation
9. Cannabinoid receptors and their endogenous agonists
10. Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses
11. Δ9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors
12. Functional coupling of the δ-, μ-, and κ-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells
13. Facilitation of brain stimulation reward by Δ9-tetrahydrocannabinol
14. A longitudinal study of marijuana effects
15. Morphine and Δ9-tetrahydrocannabinol: Two-way cross tolerance for antinociceptive and heart-rate responses in the rat
16. Interactions between cannabidiol and Δ9-THC during abstinence in morphine-dependent rats
17. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ-9-tetrahydrocannabinol
18. The inhibitory effect of fentanyl and other morphine-like analgesics on the warm induced tail withdrawal reflex in rat
19. Naloxone-induced or postwithdrawal abstinence signs in Δ9-tetrahydrocannabinol-tolerant rats
20. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations
21. Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides
22. Drugs of abuse: Anatomy, pharmacology and function of reward pathways
23. Neural substrates of opiate withdrawal
24. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
25. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors
26. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications
27. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain
28. Pharmacological and biochemical interactions between opioids and cannabinoids
29. Cocaine, but not morphine, induces conditioned place preference, sensitization to locomotor responses in CB1 knockout mice
30. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioidreceptor gene
31. Change in hypothermia and catalepsy induced by cannabinoids or morphine in mice tolerant to these substances
32. An acute dose of Δ9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity
33. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphinedependent rats
34. Pharmacological characterization of cannabinoids in the elevated plus maze
35. Potentiation of Δ9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of μand κ-opioid receptors
36. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens
37. μ-opioid receptor knockout mice do not selfadminister alcohol
38. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats
39. Antisense oligodeoxynucleotides to the kappa 1 receptor enhance Δ9-tetrahydrocannabinol-induced antinociceptive tolerance
40. Disruption of the κ-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ-agonist U-50,488H and attenuates morphine withdrawal
41. Drug use and drinking among students in 36 countries
42. Characterization of Δ9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats
43. Interactions between Δ 9-tetrahydrocannabinol and κ opioids in mice
44. Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal
45. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism
46. Evidence for a bi-directional crosstolerance between morphine and Δ9-tetrahydrocannabinol in mice
47. A behavioural model to reveal place preference to Δ9-tetrahydrocannabinol in mice
48. The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats
49. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice
50. Δ9-tetrahydrocannabinol releases, facilitates the effects of endogenous enkephalins: Reduction in morphine withdrawal syndrome without change in rewarding effect
51. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine
52. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A
53. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanineleucine, ICI 174,864 or naloxone in mice